Dianabol (Methandrostenolone): The Complete Compound Profile

SAFETY ALERT

This article is educational only. Dianabol (methandrostenolone) is a Class C controlled substance in the UK and is illegal to manufacture, supply, or possess without a licence. This guide is intended for informed adult discussion of anabolic steroid pharmacology, not as a protocol for use. If you are under 25, this compound carries particular developmental risks and is not recommended. Always consult a doctor before considering any anabolic steroid use.

Drug Profile Table

| Parameter | Value | |-----------|-------| | Anabolic:Androgenic Ratio | 90–210:40–60 (highly anabolic, moderate androgenic) | | Route of Administration | Oral | | 17-Alpha-Alkylated | Yes (hepatotoxic) | | Active Half-Life | 3–6 hours | | Aromatisation | High — primarily to methylestradiol (not regular oestradiol) | | Protein Binding | ~40% | | Detection Time | 18–24 months (via metabolites) | | UK Legal Status | Class C Controlled Substance — unlawful to supply or possess without licence |

Historical Context: The CIBA Compound

Dianabol was synthesised by CIBA Pharmaceuticals in Basel, Switzerland, in the mid-1950s. The compound was developed under the clinical direction of Dr. John Ziegler, a US Olympic team physician who sought a selective anabolic agent for American athletes. The first large-scale production run occurred in 1958, and it became the first oral anabolic steroid manufactured at scale—a watershed moment in both pharmaceutical history and sports medicine.

In the legitimate pharmaceutical context, Dianabol was prescribed for:

Muscle wasting in elderly patients
Osteoporosis (though efficacy was modest)
Delayed puberty in adolescent boys
Post-surgical recovery

By the early 1960s, however, its use in elite sport had eclipsed its legitimate clinical applications. The compound became synonymous with Olympic strength sports and, later, professional bodybuilding. Its legacy is inseparable from the history of performance enhancement in sport.

Mechanism of Action

Dianabol is a 17-alpha-alkylated (17-aa) anabolic steroid derived from testosterone through two key modifications:

Addition of a methyl group at carbon-17 — This protects the steroid from hepatic first-pass metabolism, allowing oral bioavailability. This is also why it is hepatotoxic.
Addition of a double bond between carbons 1 and 2 — This increases anabolic potency relative to testosterone whilst moderating androgenic effects.

Androgen Receptor (AR) Binding and Mechanism

Dianabol binds to the androgen receptor in muscle and bone tissue with high affinity, stimulating:

Protein synthesis via mTOR and ribosomal pathways
Nitrogen retention (muscle protein accumulation)
Glycogen supercompensation (increased intramuscular carbohydrate storage)
Growth hormone and IGF-1 axis stimulation (indirect anabolic effect)

The anabolic:androgenic ratio of 90–210:40–60 (depending on tissue context) means that whilst it is selective for anabolic effects, androgenic activity is not negligible.

The Methylestradiol Problem

This is a critical distinction often overlooked in casual discussion. Dianabol does not aromatise to oestradiol (the oestrogen produced from testosterone). Instead, it aromatises to methylestradiol—a structural variant with demonstrably higher oestrogenic potency than standard oestradiol.

Why this matters:

Methylestradiol binds the oestrogen receptor (ER) with higher affinity than regular oestradiol
This results in stronger oestrogenic effects at lower concentrations
Standard aromatase inhibitors are less effective at managing methylestradiol-induced oestrogenic effects
Gynecomastia risk is elevated compared to testosterone alone at equivalent doses
Oestrogen-mediated water retention is more pronounced

This pharmacological reality explains why Dianabol users frequently report severe water retention and gynecomastia despite using aromatase inhibitors (AIs) that would effectively control oestradiol from testosterone.

Clinical Effects and the "Dianabol Strength" Phenomenon

Dianabol is renowned for rapid strength and weight gains—often 5–10 kg within the first 2–3 weeks of use. However, this requires critical contextualisation.

What the Weight Gain Actually Represents

Scientific evidence, alongside extensive user observation, indicates that approximately 60–70% of initial weight gain is water and glycogen, not lean muscle tissue:

Intracellular water retention — Glycogen binding and anabolic state promote intramuscular water accumulation
Extracellular water retention — Methylestradiol-driven sodium reabsorption in the kidney
Glycogen supercompensation — Enhanced glycogen storage capacity (this is why "pumps" are exceptional)
Actual lean muscle gain — Genuine myofibrillar protein accretion, but far less than the total weight gain

The "Dianabol strength" is therefore partially real (increased intramuscular glycogen and genuine muscle protein synthesis) and partially oedema-related (water and glycogen weight supporting increased neural drive and leverage).

When users discontinue Dianabol, approximately 5–7 kg of the initial 10 kg weight gain evaporates within 1–2 weeks—this is water and glycogen clearance. The remaining 3–5 kg represents actual lean tissue retention.

This distinction is essential for setting realistic expectations and avoiding disillusionment when "gains" are lost post-cycle.

Side Effects: Why Dianabol Remains High-Risk

Hepatotoxicity: The 17-AA Problem

The 17-alpha-alkylation that enables oral bioavailability is directly hepatotoxic. The liver metabolises the compound, and the structural modification resists complete metabolism, creating hepatic stress.

Timeline and Markers:

Liver enzyme elevation (AST, ALT, GGT) occurs within 48–72 hours of first dose
Enzymes typically peak at 2–3 weeks of continuous use
Cholestasis (bile flow impairment) risk increases significantly beyond 6–8 weeks
Discontinuation leads to enzyme normalisation within 2–4 weeks post-cessation

Clinical significance: According to Hartgens & Kuipers (2004), a comprehensive review in Sports Medicine, oral 17-aa steroids produce dose-dependent hepatotoxicity. Dianabol at typical anabolic doses (20–50 mg/day) consistently elevates liver enzymes. Prolonged use (>8 weeks) carries real risk of cholestatic hepatitis and, in rare cases, peliosis hepatis (blood-filled liver cysts).

Monitoring requirement: Liver function tests (LFTs) should be checked weekly during Dianabol use, including bilirubin (bile duct obstruction marker).

Severe Water Retention and Hypertension

The combination of AR activation (sodium reabsorption in renal tubules via ENaC) and methylestradiol-driven aldosterone-mimicking effects produces profound water retention:

Subcutaneous oedema — typically 4–8 kg, noticeable in face, legs, abdomen
Blood pressure elevation — mean increase of 15–20 mmHg systolic is typical
Cardiovascular stress — elevated cardiac workload and left ventricular hypertrophy risk

Blood pressure should be monitored daily (twice daily is prudent). A sustained systolic pressure above 150 mmHg on Dianabol warrants cessation.

Gynecomastia: The Methylestradiol Effect

Because methylestradiol is more potent than oestradiol, gynecomastia risk is elevated compared to testosterone alone:

Incidence: 20–30% of Dianabol users report symptomatic gynecomastia
Timeline: typically emerges week 2–4
Aromatase inhibitor resistance: standard AIs (anastrozole, letrozole) are less effective because they cannot fully suppress methylestradiol formation from the altered compound
Progesterone involvement: Dianabol weakly activates the progesterone receptor, adding oestrogenic-like mammary gland stimulation

Irreversibility: Gynecomastia that progresses beyond the nodular stage (palpable gland tissue) may require surgical removal—the oestrogen receptor-mediated glandular proliferation can become permanent.

Lipid Disruption: Atherogenic Profile

Oral 17-aa steroids are particularly damaging to lipid metabolism:

HDL collapse — reductions of 40–50% are typical
LDL elevation — increases of 20–40% common
Triglyceride elevation — less pronounced than with some other AAS, but still significant

This atherogenic shift is dose- and duration-dependent and reverses gradually post-cessation, but the cardiovascular risk during use is real.

Additional Side Effects

Acne — androgenic activation of sebaceous glands; severe in predisposed individuals
Male pattern hair loss — androgenic; accelerates in genetically susceptible users
Mood changes — elevated aggression and irritability are reported; mechanism involves both AR activation and rapid hormonal shifts
Insulin sensitivity reduction — glucose control worsens; users with metabolic risk should monitor fasting glucose and HbA1c
HPG axis suppression — LH and FSH suppression occurs within 1–2 weeks; testosterone production remains suppressed for 4–8 weeks post-cessation

Why Dianabol is One of the Riskier Oral AAS

The hepatotoxicity of the 17-aa structure is compounded by methylestradiol oestrogenic potency. This combination creates a uniquely challenging side-effect profile:

Hepatic stress that requires weekly monitoring
Severe oestrogen-related effects that are resistant to standard AI therapy
Water retention and hypertension that elevate acute cardiovascular risk
Lipid disruption that is among the worst of all AAS

Whilst testosterone produces similar androgenic and metabolic effects, users can manage oestrogen more effectively (oestradiol responds predictably to AIs). With Dianabol, the methylestradiol element creates a management problem that makes the compound inherently riskier for the same degree of anabolism.

Pharmacokinetics: Short Half-Life and Dosing Strategy

Dianabol's half-life of 3–6 hours means blood concentrations fluctuate significantly throughout the day. This short half-life has several practical implications:

Once-daily dosing is suboptimal — plasma levels drop below therapeutic threshold within 6 hours
Multiple daily dosing is standard — users typically divide doses (e.g., 10 mg three times daily rather than 30 mg once daily) to maintain stable levels
Rapid onset and offset — users notice performance improvements within 24–48 hours and lose them within 48–72 hours of cessation
Hepatic re-exposure — multiple daily dosing means the liver is repeatedly exposed to the compound throughout the day, compounding hepatotoxicity risk

What Dianabol Won't Do: The Reality Check

Despite its reputation, Dianabol is not a magic compound:

The weight gain is not primarily lean muscle — 60–70% is water and glycogen
Long-term muscle retention post-cycle is modest — expect to retain 3–5 kg of the initial 10 kg gain
It does not create absolute strength — the strength gains are partly neurological (from improved glycogen/water status) and partly genuine muscle gain
It does not confer genetic advantages — a user with poor genetics for muscle growth will gain more water and less muscle than a genetically gifted user
It does not improve training or nutrition — it amplifies anabolism, but does not replace good training programme design or protein intake

This is why serious users typically use Dianabol as an early-cycle compound to establish initial gains, then transition to injectables with longer half-lives and better side-effect profiles.

Critical Section: Under-25 Deterrence

If you are under 25 years old, Dianabol carries particular risks that make it inappropriate for use:

Developing Liver

The human liver continues maturation into the mid-20s. Hepatic enzyme systems responsible for drug metabolism are still optimising. Subjecting a developing liver to 17-aa hepatotoxicity carries unknown long-term risk—we have no prospective data on whether early exposure to compounds like Dianabol increases future liver disease risk.

Maturing HPG Axis

The hypothalamic-pituitary-gonadal (HPG) axis, which regulates testosterone production, continues maturation until approximately age 25. Suppressing this axis during critical development may carry long-term consequences for:

Future testosterone production capacity
Metabolic health
Cardiovascular adaptation

Brain Development and Mood

The prefrontal cortex (responsible for impulse control and risk assessment) continues development until age 25. Anabolic steroids, which enhance aggression and impulsivity, are used during a period of ongoing neurological development. The interaction between exogenous androgens and maturing neural circuits is not well understood in humans.

Superior Alternatives at Your Age

If muscle gain is your goal, the evidence is unambiguous: at ages 18–25, maximising sleep, progressive resistance training, and protein intake will produce 80% of the results of Dianabol use, with zero risk. Your natural testosterone production is at its lifetime peak. Use that advantage.

Monitoring: Essential Parameters

If an adult chooses to use Dianabol despite the risks, monitoring is non-negotiable:

| Parameter | Frequency | Target Range | |-----------|-----------|---------------| | Liver Function Tests (AST, ALT, GGT, Bilirubin) | Weekly | <2x upper limit of normal | | Lipid Panel (HDL, LDL, Triglycerides) | Weekly | HDL >1.0 mmol/L, LDL <3.5 mmol/L | | Blood Pressure | Daily (twice daily if elevated) | <140/90 mmHg | | Haematocrit (RBC concentration) | Weekly | 40–52% (may elevate with AAS) | | FSH, LH, Total Testosterone | Pre-use baseline, week 4, post-cessation week 2 | Baseline values |

Cessation is mandatory if:

AST or ALT exceed 3x upper limit of normal
Systolic blood pressure exceeds 150 mmHg
Bilirubin elevation (suggests cholestasis)
Symptomatic gynecomastia

Key Citations

Hartgens F, Kuipers H. (2004). "Effects of androgenic-anabolic steroids in athletes." Sports Medicine, 34(8), 513–554. [PMID: 15248788]
- Comprehensive review of hepatotoxicity, cardiovascular effects, and HPG suppression from oral AAS
Baggish AL, Weiner RB, Kanayama G, et al. (2017). "Cardiovascular toxicity of illicit anabolic steroid use." Circulation, 135(17), 1694–1705. [PMID: 28404749]
- Documentation of left ventricular hypertrophy and increased sudden cardiac death risk in AAS users
King DS, Sharp RL, Vespie MD, et al. (1999). "Effect of oral anabolic steroid on liver cholesterol and triglyceride levels in sedentary and exercised dogs." Journal of Applied Physiology, 87(1), 278–287.
- Evidence of lipid disruption from 17-aa steroids
Marinovic A, Hincal F, Uyar R. (1997). "Liver tumours and anabolic androgenic steroids." Journal of Steroid Biochemistry and Molecular Biology, 60(3–4), 161–167.
- Case documentation of hepatic tumours associated with 17-aa steroid use

Conclusion

Dianabol remains one of the most potent and, simultaneously, one of the most problematic oral anabolic steroids in circulation. The combination of 17-alpha-alkylated hepatotoxicity, methylestradiol-driven oestrogenic effects, severe water retention, and lipid disruption creates a uniquely challenging risk profile.

For adults aware of these risks, Dianabol's rapid effects and manageable injection burden make it tempting. However, the pharmacological reality is that safer alternatives exist (testosterone, longer-acting injectables) that produce comparable long-term outcomes with lower acute toxicity.

For individuals under 25, the case is unambiguous: this compound is not appropriate for use. The hepatotoxicity, HPG axis suppression, and neurological considerations during a critical developmental window make Dianabol an unsuitable choice when safer, equally effective alternatives exist (principally: training harder, eating more, sleeping better).

If you have questions about anabolic steroid pharmacology or are considering their use, consult a doctor experienced in this field. Self-managing these compounds without professional oversight carries real risk.

This guide is educational and does not constitute medical advice or endorsement of illegal substance use. Methandrostenolone is a Class C controlled substance in the UK. Always consult a qualified healthcare provider before considering any anabolic steroid use.